Spyre Therapeutics, Inc. (NASDAQ:SYRE – Get Free Report) CEO Cameron Turtle sold 15,000 shares of Spyre Therapeutics stock in a transaction dated Friday, May 1st. The shares were sold at an average price of $71.37, for a total value of $1,070,550.00. Following the completion of the sale, the chief executive officer owned 612,540 shares of the company’s stock, valued at $43,716,979.80. This trade represents a 2.39% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Cameron Turtle also recently made the following trade(s):
- On Wednesday, April 1st, Cameron Turtle sold 15,000 shares of Spyre Therapeutics stock. The shares were sold at an average price of $49.33, for a total value of $739,950.00.
- On Monday, March 2nd, Cameron Turtle sold 15,000 shares of Spyre Therapeutics stock. The shares were sold at an average price of $42.19, for a total value of $632,850.00.
- On Monday, February 2nd, Cameron Turtle sold 15,000 shares of Spyre Therapeutics stock. The shares were sold at an average price of $32.80, for a total value of $492,000.00.
Spyre Therapeutics Price Performance
SYRE opened at $69.42 on Monday. The stock has a market capitalization of $5.47 billion, a price-to-earnings ratio of -33.38 and a beta of 3.12. The business has a 50-day moving average of $51.75 and a two-hundred day moving average of $37.61. Spyre Therapeutics, Inc. has a 12 month low of $12.28 and a 12 month high of $76.00.
Hedge Funds Weigh In On Spyre Therapeutics
A number of institutional investors have recently made changes to their positions in SYRE. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of Spyre Therapeutics by 18.8% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 27,018 shares of the company’s stock valued at $442,000 after purchasing an additional 4,277 shares in the last quarter. JPMorgan Chase & Co. raised its position in shares of Spyre Therapeutics by 13.8% in the 2nd quarter. JPMorgan Chase & Co. now owns 47,279 shares of the company’s stock valued at $708,000 after purchasing an additional 5,723 shares in the last quarter. Rhumbline Advisers raised its position in shares of Spyre Therapeutics by 30.6% in the 2nd quarter. Rhumbline Advisers now owns 73,168 shares of the company’s stock valued at $1,095,000 after purchasing an additional 17,145 shares in the last quarter. New York State Common Retirement Fund raised its position in shares of Spyre Therapeutics by 61.4% in the 2nd quarter. New York State Common Retirement Fund now owns 16,565 shares of the company’s stock valued at $248,000 after purchasing an additional 6,300 shares in the last quarter. Finally, Invesco Ltd. raised its position in shares of Spyre Therapeutics by 37.6% in the 2nd quarter. Invesco Ltd. now owns 34,680 shares of the company’s stock valued at $519,000 after purchasing an additional 9,473 shares in the last quarter. 80.39% of the stock is owned by institutional investors and hedge funds.
Wall Street Analyst Weigh In
SYRE has been the subject of a number of research reports. Jefferies Financial Group boosted their target price on Spyre Therapeutics from $47.00 to $85.00 and gave the stock a “buy” rating in a report on Monday, April 13th. Wells Fargo & Company boosted their target price on Spyre Therapeutics from $50.00 to $90.00 and gave the stock an “overweight” rating in a report on Tuesday, April 14th. JonesTrading boosted their target price on Spyre Therapeutics from $64.00 to $95.00 and gave the stock a “buy” rating in a report on Friday, April 17th. Wall Street Zen cut Spyre Therapeutics from a “hold” rating to a “sell” rating in a report on Sunday, April 26th. Finally, Wedbush boosted their target price on Spyre Therapeutics from $65.00 to $80.00 and gave the stock an “outperform” rating in a report on Monday, April 13th. Two research analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Buy” and a consensus target price of $85.08.
Check Out Our Latest Stock Report on SYRE
More Spyre Therapeutics News
Here are the key news stories impacting Spyre Therapeutics this week:
- Positive Sentiment: Yahoo Finance ran a feature asking whether Spyre is one of the small-cap stocks “on fire,” highlighting recent momentum and investor interest that can support valuation and liquidity. Is Spyre Therapeutics (SYRE) One of the Small-Cap Stocks That Are On Fire Right Now?
- Neutral Sentiment: Spyre’s Compensation Committee approved inducement stock options totaling 20,800 shares for four non-executive hires — a common hiring tool; dilution is small but notable if hiring accelerates. Spyre Therapeutics Announces Grants of Inducement Awards
- Negative Sentiment: CEO Cameron Turtle sold 15,000 shares at ~$71.37 under a 10b5-1 plan (?$1.07M); although planned, large insider sales can signal executives taking profits after the run-up. SEC Form 4 — Cameron Turtle
- Negative Sentiment: Insider Sheldon Sloan sold 78,333 shares at ~$71.50 (~$5.6M), reducing his position by half via a 10b5-1 plan — a large, headline-grabbing sale that likely pressured sentiment. SEC Form 4 — Sheldon Sloan
- Negative Sentiment: CFO Scott L. Burrows sold 12,500 shares at ~$71.37 (~$892k) under a 10b5-1 plan, trimming ~11% of his holdings — another insider sale adding to downward pressure. SEC Form 4 — Scott L. Burrows
Spyre Therapeutics Company Profile
Spyre Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel immunotherapies for cancer. The company leverages proprietary protein engineering and biologics design platforms to create targeted molecules intended to enhance anti-tumor immune responses and inhibit tumor growth. Its preclinical pipeline comprises multiple candidate therapies for solid tumor and hematologic oncology indications.
Established by a team with deep expertise in protein design, immunology and translational research, Spyre Therapeutics collaborates with leading academic institutions and research organizations to accelerate its discovery efforts.
Featured Articles
Receive News & Ratings for Spyre Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spyre Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
